NC-PERCONA
20.12.2021 15:02:10 CET | Business Wire | Press release
Percona , a leader in open source database software and services, celebrated record growth for Q3 2021, including 44 percent Annual Recurring Revenue (ARR) growth year over year. With more than 10 million downloads of its open source projects and tools, Percona actively enables developers and database administrators in their roles powering business applications.
Percona brings together database distributions alongside open source tools and contributions to build enterprise-ready database products. This model represents the potential of the open source approach to make a real difference in how developers build the applications that their companies need and how DBAs manage their database environment most effectively.
“We support global retail customers with their critical payment infrastructure, and we plan ahead so that we can always deliver what our customers need. Percona offers round-the-clock expert support to ensure our databases are running at peak performance. We can rely on Percona’s unbiased approach as we consider any future deployments too,” said Delia Pedersoli, Chief Operating Officer at MultiPay.
Percona continues to take an independent approach to open source and databases, collaborating with a wide range of organizations across industries. Since inception, the company’s services and support expertise for managing, scaling, and optimizing database performance has been infrastructure agnostic. This supports customers to achieve value faster, deliver better availability for their applications and achieve flexibility in deployment to help their organizations win. Percona has recently expanded its approach, including the recent announcement of its new unified Percona Platform for multiple database distributions, management tools, private Database as a Service (DBaaS), and support.
“Our future as a company is based on packaging up our skills and experience in new ways, beginning with Percona Platform. The platform will make it easier for developers and DBAs to get the value of the work that we have put in over the years, bringing everything together in one place. We’ll continue to support customers running individual databases, whether they are running our distributions or not, as this is part of the value that open source provides to the market, as well as expanding how we deliver our expertise over time,” said Ann Schlemmer, President at Percona.
"Over the last decade-plus, the typical enterprise has seen a dramatic expansion in the number and type of databases leveraged. In many cases, the only thing that the databases have had in common was the fact that they were open source," said Stephen O'Grady, Principal Analyst with RedMonk. "This presented challenges for buyers, however, as negotiating with an ever-growing number of infrastructure vendors was both difficult to scale and limited the leverage buyers could bring to bear. What many have been looking for is a single vendor to supply them with support for multiple databases, and this is the exact opportunity Percona has targeted."
Percona was founded to support companies that wanted to run open source databases for their applications and remains fully committed to the ideals of free and open source software. The company celebrated its 15th anniversary in 2021, and has grown by embracing remote work and flexibility from the start. Today, Percona has staff based across 42 countries.
An overview of Percona’s anniversary is available at https://www.percona.com/about-percona/15th-anniversary and Percona Platform is available as a preview at https://www.percona.com/platform-preview .
Links
- Percona Products - https://www.percona.com/software
- Percona database optimization services - https://www.percona.com/solutions/optimize-database-performance
About Percona
Databases run better with Percona. Percona is the only company that delivers enterprise-class products, support and services for a range of open source databases including MySQL®, MariaDB®, MongoDB®, and PostgreSQL across traditional deployments, cloud-based platforms and hybrid IT environments. The company is committed to supporting open source as an approach to software licensing, development and deployment - its database management tools are used by millions of application developers, database administrators and IT professionals worldwide.
Percona equips businesses with the freedom to choose, the freedom to create, and the freedom to make a difference — helping them scale with speed as they grow. The company supports global brands such as PayPal, Vimeo, RockStar Games, Duolingo, Fiserv, Slack, Cisco Systems, and Rent the Runway, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. For more information, visit www.percona.com .
Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005345/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom